Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myeloid-derived suppressor cells coming of age
Filippo Veglia, Michela Perego, Dmitry I. Gabrilovich
Nature Immunology (2018) Vol. 19, Iss. 2, pp. 108-119
Open Access | Times Cited: 1522

Showing 1-25 of 1522 citing articles:

Inflammation and Cancer: Triggers, Mechanisms, and Consequences
Florian R. Greten, Sergei I. Grivennikov
Immunity (2019) Vol. 51, Iss. 1, pp. 27-41
Open Access | Times Cited: 2715
Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta, Jeffrey W. Pollard
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 12, pp. 887-904
Open Access | Times Cited: 1566
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Jonas Schulte-Schrepping, Nico Reusch, Daniela Paclik, et al.
Cell (2020) Vol. 182, Iss. 6, pp. 1419-1440.e23
Open Access | Times Cited: 1374
Tumor-Associated Macrophages in Tumor Immunity
Yueyun Pan, Yinda Yu, Xiaojian Wang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 1288
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Filippo Veglia, Emilio Sanseviero, Dmitry I. Gabrilovich
Nature reviews. Immunology (2021) Vol. 21, Iss. 8, pp. 485-498
Open Access | Times Cited: 1216
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Daniela Bruni, Helen K. Angell, Jérôme Galon
Nature reviews. Cancer (2020) Vol. 20, Iss. 11, pp. 662-680
Closed Access | Times Cited: 1183
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy
Lei Xu, Yu Lei, Jin-ke Li, et al.
Cancer Letters (2019) Vol. 470, pp. 126-133
Closed Access | Times Cited: 1109
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 8, pp. 525-543
Open Access | Times Cited: 913
The lung microenvironment: an important regulator of tumour growth and metastasis
Nasser K. Altorki, Geoffrey J. Markowitz, Dingcheng Gao, et al.
Nature reviews. Cancer (2018) Vol. 19, Iss. 1, pp. 9-31
Open Access | Times Cited: 894
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
Peter van Galen, Volker Hovestadt, Marc H. Wadsworth, et al.
Cell (2019) Vol. 176, Iss. 6, pp. 1265-1281.e24
Open Access | Times Cited: 863
Neutrophil diversity and plasticity in tumour progression and therapy
Sébastien Jaillon, Andrea Ponzetta, Diletta Di Mitri, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 9, pp. 485-503
Closed Access | Times Cited: 850
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
Aymeric Silvin, Nicolas Chapuis, Garett Dunsmore, et al.
Cell (2020) Vol. 182, Iss. 6, pp. 1401-1418.e18
Open Access | Times Cited: 776
Tumour-associated neutrophils in patients with cancer
Merav E. Shaul, Zvi G. Fridlender
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 10, pp. 601-620
Closed Access | Times Cited: 739
How the ageing microenvironment influences tumour progression
Mitchell E. Fane, Ashani T. Weeraratna
Nature reviews. Cancer (2019) Vol. 20, Iss. 2, pp. 89-106
Open Access | Times Cited: 582
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Christopher M. Jackson, John Choi, Michael Lim
Nature Immunology (2019) Vol. 20, Iss. 9, pp. 1100-1109
Closed Access | Times Cited: 572
Toll-like receptors in immunity and inflammatory diseases: Past, present, and future
Vijay Kumar
International Immunopharmacology (2018) Vol. 59, pp. 391-412
Open Access | Times Cited: 570
Neutrophils as emerging therapeutic targets
Tamás Németh, Markus Sperandio, Attila Mócsai
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 4, pp. 253-275
Closed Access | Times Cited: 535
Fatty acid transport protein 2 reprograms neutrophils in cancer
Filippo Veglia, Vladimir A. Tyurin, Maria Blasi, et al.
Nature (2019) Vol. 569, Iss. 7754, pp. 73-78
Open Access | Times Cited: 534
Heterogeneity of neutrophils
Lai Guan Ng, Renato Ostuni, Andrés Hidalgo
Nature reviews. Immunology (2019) Vol. 19, Iss. 4, pp. 255-265
Closed Access | Times Cited: 515
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Kai Li, Houhui Shi, Benxia Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 492
The hallmarks of successful anticancer immunotherapy
Lorenzo Galluzzi, Timothy A. Chan, Guido Kroemer, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 459
Open Access | Times Cited: 487
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber, Viktor Fleming, Xiaoying Hu, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 467
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy
Martina Molgora, Ekaterina Esaulova, William Vermi, et al.
Cell (2020) Vol. 182, Iss. 4, pp. 886-900.e17
Open Access | Times Cited: 458
Monocyte heterogeneity and functions in cancer
Claire Olingy, Huy Q. Dinh, Catherine C. Hedrick
Journal of Leukocyte Biology (2019) Vol. 106, Iss. 2, pp. 309-322
Open Access | Times Cited: 454
MDSC: Markers, development, states, and unaddressed complexity
Samarth Hegde, Andrew M. Leader, Miriam Mérad
Immunity (2021) Vol. 54, Iss. 5, pp. 875-884
Open Access | Times Cited: 447
Page 1 - Next Page

Scroll to top